IR 999
Alternative Names: IR-999; SepsicillinLatest Information Update: 28 Jul 2018
At a glance
- Originator Immune Response BioPharma
- Class Biological proteins
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sepsis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Sepsis in USA
- 17 May 2016 Preclinical development is ongoing (Immune Response Biopharma pipeline, May 2016)
- 01 Mar 2011 Preclinical trials in Sepsis in USA (unspecified route)